Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$57.93

0.71 (1.24%)

07:19
05/19/17
05/19
07:19
05/19/17
07:19

Alkermes added depression drug data a positive, says Credit Suisse

Credit Suisse analyst Vamil Divan said he views the additional ALKS 5461 FORWARD-5 study data that Alkermes presented as an incremental positive, adding that the safety profile of the prospective depression treatment also seems clean. A "leading psychiatrist" that Divan met with now feels more comfortable that the data for ALKS 5461 should be sufficient for FDA approval, the analyst tells investors. He keeps an Outperform rating and $70 target price on Alkermes shares.

  • 19

    May

  • 06

    Jun

  • 08

    Jun

ALKS Alkermes
$57.93

0.71 (1.24%)

04/27/17
JEFF
04/27/17
NO CHANGE
Target $69
JEFF
Buy
Jefferies trims Alkermes target to $69 after Q1 miss
Jefferies analyst Biren Amin attributes Alkermes' Q1 miss to Vivitrol and lowered his price target for the shares to $69 from $70. The analyst keeps a Buy rating on the name. Management blamed inventory destocking for the weaker than expected Vivitrol sales and reiterated the drug's outlook for 2017, Amin tells investors in a post-earnings research note. He expects the challenges Aristada observed from higher gross to net rebates in the quarter to stabilize in the second half of 2017.
04/27/17
JPMS
04/27/17
NO CHANGE
Target $78
JPMS
Overweight
JPMorgan keeps Overweight rating on Alkermes after Q1 miss
JPMorgan analyst Cory Kasimov attributes Alkermes' Q1 miss to "commercial seasonality and pricing." He points out management reiterated 2017 guidance and highlighted that underlying trends for both Aristada and Vivitrol remain strong. The analyst continues to believe the legacy base business, combined with the growth potential of Vivitrol and Aristada and the optionality of the wholly owned late-stage pipeline, offers an "attractive combo" for investors. Kasimov keeps an Overweight rating on Alkermes with a $78 price target.
05/01/17
FBCO
05/01/17
NO CHANGE
Target $70
FBCO
Outperform
Alkermes price target lowered to $70 from $78 at Credit Suisse
Credit Suisse analyst Vamil Divan lowered his price target for Alkermes to $78 from $70 after Q1 results. The analyst reiterates an Outperform rating, and notes that his enthusiasm on Alkermes remains driven by the upside he expects from Vivitrol in the near to mid-term and then the pipeline over time.
05/18/17
LEER
05/18/17
NO CHANGE
LEER
Outperform
Leerink sees 'multiple approvability questions' for Alkermes in depression
Leerink analyst Paul Matteis believes "multiple approvability questions" remain after Alkermes this morning presented additional clinical data for ALKS 5461 in treatment resistant depression. The FDA's acceptance of a novel trial design and tweaked clinical endpoint are among the outstanding issues, Matteis tells investors in a research note. Today's data are unlikely to "materially shift the debate in the short term," the analyst adds. Matteis, however, remains "encouraged by the breadth of precedent for FDA flexibility in psychiatry" ahead of an ALKS 5461 new drug application filing in the second half of the year. He reiterates an Outperform rating on Alkermes. The stock in afternoon trading is up 57c to $57.79.

TODAY'S FREE FLY STORIES

WHR

Whirlpool

$182.50

0.04 (0.02%)

07:20
10/24/17
10/24
07:20
10/24/17
07:20
Technical Analysis
Technical View: Whirlpool down sharply as results, view, miss expectations »

The stock is set to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 14

    Nov

07:20
10/24/17
10/24
07:20
10/24/17
07:20
General news
FX Update: The dollar has traded firmer »

FX Update: The dollar has…

GLW

Corning

$30.01

-0.05 (-0.17%)

07:19
10/24/17
10/24
07:19
10/24/17
07:19
Hot Stocks
Corning sees every business segment to meet or beat plan in Q4 »

"Year-to-date…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

HNI

HNI Corporation

$42.29

-0.57 (-1.33%)

07:19
10/24/17
10/24
07:19
10/24/17
07:19
Downgrade
HNI Corporation rating change  »

HNI Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

PTCT

PTC Therapeutics

$16.99

-0.8 (-4.50%)

07:19
10/24/17
10/24
07:19
10/24/17
07:19
Conference/Events
Breaking Conference/Events news story on PTC Therapeutics »

FDA PDUFA Date for PTC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 02

    Nov

  • 06

    Nov

GLW

Corning

$30.01

-0.05 (-0.17%)

07:18
10/24/17
10/24
07:18
10/24/17
07:18
Earnings
Corning reports Q3 core EPS 43c, consensus 41c »

Reports Q3 GAAP revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

HYGS

Hydrogenics

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Conference/Events
TMX Group to hold a conference »

TSX Industrial &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 16

    Nov

THR

Thermon Group

$21.40

0.4 (1.90%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Recommendations
Thermon Group analyst commentary  »

Thermon Group price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGA

Pegasystems

$59.15

-0.3 (-0.50%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Recommendations
Pegasystems analyst commentary  »

Pegasystems should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHW

Sherwin-Williams

$386.58

-3.12 (-0.80%)

07:16
10/24/17
10/24
07:16
10/24/17
07:16
Technical Analysis
Technical View: Sherwin-Williams slips lower after results »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

ELVT

Elevate Credit

$7.52

-0.14 (-1.83%)

, FPAY

FlexShopper

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Conference/Events
Stephens to hold meetings at conference »

Stephens Hosted Company…

ELVT

Elevate Credit

$7.52

-0.14 (-1.83%)

FPAY

FlexShopper

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 30

    Oct

CTMX

CytomX Therapeutics

$20.04

-0.12 (-0.60%)

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Initiation
CytomX Therapeutics initiated  »

CytomX Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$171.27

-3.71 (-2.12%)

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Periodicals
Facebook faces EU-wide privacy fights after top court setback, Bloomberg says »

Facebook may faces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 01

    Nov

  • 08

    Nov

  • 15

    Nov

HFC

HollyFrontier

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Downgrade
HollyFrontier rating change  »

HollyFrontier downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

PBF

PBF Energy

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Downgrade
PBF Energy rating change  »

PBF Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPX

Louisiana-Pacific

07:15
10/24/17
10/24
07:15
10/24/17
07:15
Initiation
Louisiana-Pacific initiated  »

Louisiana-Pacific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VLO

Valero

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Downgrade
Valero rating change  »

Valero downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

DK

Delek US

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Upgrade
Delek US rating change  »

Delek US upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

ALDW

Alon USA Partners

$11.74

0.05 (0.43%)

07:14
10/24/17
10/24
07:14
10/24/17
07:14
Upgrade
Alon USA Partners rating change  »

Alon USA Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Conference/Events
Drug Information Association to hold a conference »

Biosimilars Conference is…

PEBO

Peoples Bancorp

$33.03

-0.79 (-2.34%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Earnings
Peoples Bancorp reports Q3 EPS 60c, consensus 50c »

Reports Q3 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

WY

Weyerhaeuser

$34.82

-0.46 (-1.30%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Initiation
Weyerhaeuser initiated  »

Weyerhaeuser initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

ALXN

Alexion

$135.21

-3.81 (-2.74%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Recommendations
Alexion analyst commentary  »

Alexion could be up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

  • 06

    Nov

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:13
10/24/17
10/24
07:13
10/24/17
07:13
Hot Stocks
Breaking Hot Stocks news story on Pentair »

Pentair: Separation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNR

Pentair

$70.82

-0.35 (-0.49%)

07:12
10/24/17
10/24
07:12
10/24/17
07:12
Earnings
Pentair sees FY17 adjusted EPS $3.53, consensus $3.51 »

Sees FY17 sales $4.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.